CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

(2013) M. L. Green et al.   BLOOD

A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group

(2012) B. George et al.   Transplant Infectious Disease

CMV: when bad viruses turn good

(2011) A. J. Barrett   BLOOD

Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients

(2011) A. H. Elmaagacli et al.   BLOOD

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

(2011) B. Foley et al.   BLOOD

Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion

(2010) Martin Schmidt-Hieber et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy

(2010) B. George et al.   Transplant Infectious Disease